Abstract:Abstract Abstract 140 Background Arsenic trioxide increases the rate of complete remission (CR) and prolongs long-term overall survival in patients with acute promyelocytic leukemia (APL). We demonstrated that an oral arsenic-containing Realgar-Indigo naturalis formula (RIF) could yield clear synergistic effects in an in vivo murine APL model as well as an in vitro APL cell lines. The efficacy and safety of this formula were confirmed by a CR rate of 96.7% and reasonable safety profile in a multicenter Phase II clinical trial in China. To find out whether oral RIF could achieve similar remission and survival with ATO, the Chinese APL Cooperative Group conducted a phase 3 randomized study (APL07) that compared oral RIF with ATO in both the induction and maintenance therapies. Methods In this phase 3 randomized trial, 242 newly diagnosed APL patients were randomly assigned to receive oral RIF (n=121, daily 60 mg per kg body weight) or ATO (n=121, daily 0.15 mg per kg body weight) as a part of induction therapy. All patients also received all-trans-retinoic acid (ATRA; daily 25 mg per square meter) as induction therapy, and were between the ages of 15 and 60 years. After achieving CR, all patients were given three courses of consolidation chemotherapy with anthracycline and cytosine arabinoside. The maintenance treatment included eight cycles of sequential use of ATRA and RIF or ATO for two years. The primary endpoint was disease-free survival (DFS). The secondary endpoints were the rate of CR and overall survival (OS) and safety. Results At a median follow-up of 28 months, no significant differences were noted between RIF group and ATO group with respect to CR rate (99.1% vs.97.2%, P=0.62), DFS (98.9% vs.97.64%, P=0.6) (Figure 1A) and OS at 3 years (99.1% vs.96.6%, P=0.18) (Figure 1B). The rates of adverse events were similar in the two groups. The rate of treatment-related grade 3/4 liver toxic effects was 9.6% in the RIF group and 12.0% in the ATO group(p=0.67). When on the arsenic-containing treatment, the plasma arsenic content was higher in the ATO group than in the RIF group (56.3 vs. 23.6 μg/L, p=0.0002). The median levels of arsenics concentration of plasm, urine, hair and nail samples after completing therapy 12 months were below the lower limit of the normal control. Conclusions Oral Realgar-Indigo naturalis formula yielded a comparable high remission and long-term survival with arsenic trioxide as front-line treatment of newly diagnosed APL. Disclosures: No relevant conflicts of interest to declare.

In Vitro Study on Realgar Induced Apoptosis of All-trans Acid Resistant Acute Promeylocytic Leukemia Cell Line (MR2)

Realgar-induced Apoptosis and Differentiation in All-Trans Retinoic Acid (Atra)-Sensitive NB4 and ATRA-resistant MR2 Cells

A clinical study of Realgar on ATRA-resistant acute promyelocytic leukemia and its effects on apoptosis induction

The dual effects of realgar on acute promyelocytic leukemia cell:inducing apoptosis and promoting differentiation

Realgar (As4S4), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway in vitro

Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC‑1.

Oral Realgar-Indigo Naturalis Formula Achieved Comparably High Rate Of Remission And Survival To Intravenous Arsenic Trioxide As A Front-Line Treatment In Newly Diagnosed Acute Promyelocytic Leukemia: A Multi-Center Randomized Trial Aplo7

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia

[Establishment of Two-Dimensional Electrophoresis Proteomic Profiles of Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells with Apoptosis Induced by Realgar].

[Effect of Realgar on Induction of Apoptosis in DLBCL Cell Line SU-DHL-4 and Its Possible Mechanisms].

Effects of Realgar on Telomerase Activity and Cell Apoptosis in K562 Cells

A Novel Realgar-Indigo Naturalis Formula More Effectively Induces Apoptosis in NB4 Cells

Dissection Of Mechanisms Of Realgar Intervening Telomere Protein Pot1, Trf1, Trf2 Expression To Regulate Telomere Dynamics In Thp-1 Cells

Realgar Bioleaching Solution Induced Apoptosis in K562/ADM Calls and Its Mechanisms

The apoptosis of multi-drug resistant leukemia cells induced by realgar nanoparticle

[Proteomic Study of Retinoid Acid Resistant NB4R1 Cells Apoptosis Induced by Realgar].

Membrane Toxicity Accounts for Apoptosis Induced by Realgar Nanoparticles in Promyelocytic Leukemia HL-60 Cells

Abstract 2110: Realgar Exerts Cytotoxic Killing of Gastric Cancer Cells Through Bax Apoptotic Pathway.

Anticancer Effect of Realgar Nanoparticles on Mouse Melanoma Skin Cancer in Vivo Via Transdermal Drug Delivery

Anticancer Effect of Realgar on Human Hepatocarcinoma Cell Line BEL-7402

The Apoptosis of Lung Cancer A549 Cell Induced by Realgar and Realgar Nanoparticle